Polypeptide promoting platelet aggregation

Abstract

The invention discloses polypeptide PEP1 promoting platelet aggregation, belongs to the field of medical biotechnology, and in particular relates to a novel polypeptide having the function of promoting platelet aggregation. The polypeptide PEP1 is a polypeptide consisting of 14 amino acids, having a sequence of SEQ ID NO: 1, and having a molecular weight of 1564.77Da, and the sequence of the polypeptide PEP1 is Thr-Ile-Tyr Pro-Asn-Ala-Ser-Leu-Leu-Ile-Gln-Asn-Val-Thr. The polypeptide has a significant promoting effect on thrombin-induced platelet aggregation, can be used to explore the influence of the polypeptide PEP1 and other platelet activators on the effect and related functions of platelets, can also be used to monitor existing antiplatelet therapy, and can be applied to preparation of drugs for promoting platelet aggregation, stopping bleeding and treating cardiovascular diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and in particular relates to a polypeptide capable of promoting platelet aggregation. Background technique [0002] Cardiovascular and cerebrovascular diseases mainly include acute myocardial infarction, cerebral infarction, pulmonary infarction, ischemic heart disease, stroke and other common diseases, which seriously threaten human health and life and are the first cause of death among Chinese residents [1]. Platelet activation is an important initiating factor in the occurrence and development of cardiovascular and cerebrovascular diseases, and platelet activation, adhesion and aggregation to thrombus formation are a series of cascade reactions, which not only play a key role in the physiological hemostasis process, but also Participate in pathological processes such as thrombosis and tissue repair[2,3]. Platelet aggregation plays a central role in thrombus formation. Inducers o...

AI Technical Summary

Problems solved by technology

[0011] However, the existing antiplatelet drugs not only have side effects such as bleeding tendency (cerebral hemorrhage, gastrointestinal hemorrhage) [21], but also have resistance or low response in clinical application, and adverse ischemic events still occur; at the same time, the effects of these drugs The mechanism is single, and the antiplatelet effect has certain limitations: for example, aspirin irreversibly blocks the synthesis of COX-1, thereby inhibiting platelet activation and aggregation[10,22]; clopidogrel irreversibly inhibits the binding of ADP to its receptor P2Y12, and inhibits the induction of ADP platelet aggregation[23]; ticagrelor reversibly interacts with the ADP-P2Y12 receptor, and also inhibits ADP-induced platelet aggregation[24]; Vorapaxar and Atopaxar are PAR-1 inhibitors currently in clinical trials, which can Inhibit thrombin-induced platelet aggregation[25,26]; Abciximab, tirofiban, and eptifibatide are all GPⅡb / Ⅲa receptor antagonists[27]

Images